

Fact Sheet

Corporate Vision

Oceana Therapeutics is a private, global specialty company focused on GI and urology healthcare and committed to commercializing best-in-class therapeutics to address unmet medical needs, achieve optimal outcomes, and enhance patient quality of life.

Corporate Profile

With executive offices in Edison, NJ and European operations headquartered in Dublin, Ireland, Oceana Therapeutics is well positioned to actively pursue worldwide opportunities to identify, acquire, and maximize the therapeutic value of in-market and late-stage development products addressing the medical needs of healthcare providers and the patients they serve.

Led by award winning industry veterans John T. Spitznagel, Chairman & CEO, and David S. Tierney, MD, President and COO, Oceana was founded in 2008 and has brought together a highly experienced team of life science professionals, many having previously collaborated in successfully pioneering the business model of acquiring, developing and commercializing novel pharmaceutical products or product candidates.

Supported by the strength of its management team and its global resources, Oceana is redefining that growth model to set new standards of therapeutic excellence. Oceana Therapeutics has broadened the model beyond the U.S. to pursue international product opportunities, including specialty medical devices, and diagnostics in addition to pharmaceuticals.

By mid-2009, within one year of start-up, Oceana acquired its first commercial assets and has since initiated global operations while actively pursuing opportunities to acquire late-stage products.

QUICK FACTS

CORPORATE ADDRESS

2035 Lincoln Blvd.
Suite 2150
Edison, NJ 08817

T: 732-318-3800
F: 732-318-3801

info@OceanaThera.com
www.OceanaThera.com

STRATEGIC FOCUS Specialty Therapeutics

EXECUTIVE OFFICERS
Chairman & CEO
John T. Spitznagel

President & COO
David S. Tierney, MD

Chief Financial Officer
Andrew J. Einhorn



2010 MD+DI Honoree

Fact Sheet

Deflux[®]

Deflux[®] is used for the treatment of Vesicoureteral reflux (VUR) - a malformation of the urinary bladder which affects children and can result in severe infections of the kidney and even irreversible kidney damage. The product has both U.S. and international approvals and is marketed by Oceana through its direct sales force and distribution network. Deflux represents the only minimally invasive FDA approved alternative to major ureteral reimplantation surgery. Deflux is also used for other indications outside of the United States.

For more information about VUR and Deflux, including full prescribing and safety information and resources for Parents (Patients) and Healthcare Providers, please visit the Deflux U.S. and International websites at Deflux.com

Solesta[®]

Solesta[®] is a one-of-a-kind product for the treatment of fecal (bowel) incontinence, a condition afflicting numerous people. The loss of bowel control can be a debilitating life-limiting health problem that can cause severe patient embarrassment and even social withdrawal.

Solesta has been developed to address the large treatment gap that exists between conservative therapies for bowel incontinence such as dietary control and more involved, invasive treatments such as surgery. It is a biocompatible bulking agent consisting of an injectable gel that can be administered as a minimally invasive treatment for bowel incontinence in an outpatient setting and without the need for anesthesia.

The Premarketing Approval Application (PMA) for Solesta was submitted to the FDA in April 2010 for the treatment of fecal incontinence in adult patients who have failed conservative therapy (i.e., diet, fiber therapy, anti-motility medications). The FDA granted approval in late May 2011 and Oceana is preparing to launch Solesta into the U.S. market well before year-end. For additional information visit SolestaInfo.com.

MANAGEMENT HONORS/AWARDS



John T. Spitznagel
David S. Tierney, MD
2011 – NJ Emerging Company
David S. Tierney, MD
2005 – NJ Manufacturing
John T. Spitznagel
2004 – NJ Pharmaceuticals



John T. Spitznagel
2010 & 2006
David S. Tierney, MD
2011, 2006 & 2005



Andrew J. Einhorn
2010 Growth Management



David S. Tierney, MD
2010 Inaugural List



Andrew J. Einhorn
2005 Deal of the Year